Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, J.S. Elborn et al.|New England Journal of Medicine|2015Cited by 1.6k
A revised airway epithelial hierarchy includes CFTR-expressing ionocytesDaniel T. Montoro, Jayaraj Rajagopal, Adam L. Haber et al.|Nature|2018Cited by 1.3k
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> MutationFrank J. Accurso, Bonnie W. Ramsey, Jiuhong Zha et al.|New England Journal of Medicine|2010Cited by 802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Steven M. Rowe et al.|Thorax|2011Cited by 496
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Scott C. Bell et al.|The Lancet Respiratory Medicine|2014Cited by 442